Oxford, UK, 08 Nov 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that Founder and Chief Medical Officer Prof David Kerr CBE had been conferred the “Tianfu Friendship Award” by the Sichuan Provincial…
Oxford, UK, 22 Sep 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today that Founder and Chief Medical Officer Prof David Kerr had been made a Fellow of the European Society for Medical Oncology.…
Oxford, UK, 15 August 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announces today that in partnership with the Chinese University of Hong Kong it has successfully received a study grant from the Hong Kong government’s…
Oxford, UK, 29 June 2022 – Celleron Therapeutics, the UK-based company developing innovative precision cancer medicines, announced today a 3-year survival rate of 7.3% in late-stage micro-satellite stable colorectal cancer patients in their Phase II clinical trial, following treatment with…
Oxford, UK, 7 April 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a Phase I clinical trial cancer patient who continues to benefit from continuous zabadinostat therapy for over 2 years. CXD101-0901 is…
Oxford UK, 20 January 2022 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, announced today a 14.5% patient two-year survival rate following treatment in their Phase II clinical trial testing the immune check point inhibitor (ICI)…
Oxford, UK, 30 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the adoption of a precision medicine biomarker platform in its registrational immune combination therapy study in colorectal cancer patients. CAROSELL Clinical Study…
Oxford, UK, 8 November 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the appointment of Dr Katherine Innes-Ker to its Board of Directors. Dr Katherine Innes Ker BA (Hons), DPhil, has been appointed…
Oxford, UK, 27th Sep 2021 – Celleron Therapeutics, the UK-based company developing novel medicines for cancer patients, today announced the appointment of Richard Taylor to its Board of Directors. Richard Taylor MA ACMA has been appointed as a Non-Executive Director…
Oxford, August 25, 2021 – Celleron Therapeutics, the UK-based company developing personalised medicines for cancer patients, today announced that it has appointed Mr James Noble as its new Board Chairman. James Noble MA FCA has held a number of high-profile…